Table 1.

Characteristics of case–control studies included in VEGF +C936T polymorphism and breast cancer risk

First author	Year	Country	Ethnicity	Genotyping methods	Source of control	Cases			Controls
						CC	CT	TT	CC	CT	TT
Luo	2013	China	Asian	PCR-RFLP	HB	446	210	24	426	204	50
Rodrigues	2012	Span	Caucasian	PCR-RFLP	PB	366	76	5	332	99	11
Absenger	2013	Austria	Caucasian	TaqMan	PB	371	138	12	580	201	20
Oliveira	2011	Brazil	Mix	PCR-RFLP	PB	190	43	2	176	52	7
Lin	2009	China	Asian	PCR-RFLP	HB	155	59	6	211	117	6
Jakubowska	2008	Poland	Caucasian	PCR-RFLP	PB	245	67	7	202	81	7
Balasubramanian	2007	England	Caucasian	TaqMan	PB	624	204	20	531	165	12
Kataoka	2006	China	Asian	Taqman	PB	744	334	31	793	351	51
Jacobs	2006	USA	Mix	Taqman	PB	360	110	10	353	111	15
Jin(a)	2005	Polish	Caucasian	PCR-RFLP	PB	298	10	14	297	114	11
Jin(b)	2005	German	Caucasian	PCR-RFLP	PB	120	31	2	128	31	4
Jin(c)	2005	Swenden	Caucasian	PCR-RFLP	PB	708	204	12	720	203	11
Krippl	2003	Austria	Caucasian	Taqman	PB	412	79	9	353	137	10

PCR-RFLP polymerase chain reaction–restriction fragment length polymorphism, HB hospital based, PB population based